Articles tagged with Flu Vaccines
Current health policy based on voluntary vaccinations is not enough to control severe flu epidemics and pandemics unless vaccination programs offer incentives to individuals. Free vaccinations for entire families could actually increase the frequency of severe epidemics, according to UCLA researchers.
A national study led by Saint Louis University School of Medicine is investigating the effectiveness of a new investigational vaccine made by Bavarian Nordic in stimulating an immune response against smallpox. The study aims to determine how quickly people can be protected after a release of smallpox into the environment.
Research shows that influenza epidemics are associated with a rise in deaths from heart disease and flu can trigger heart attacks. The study highlights the importance of increasing vaccination rates in people at risk of coronary heart disease.
A new experimental flu vaccine made in insect cells has been shown to be safe and effective in protecting against the flu, with a stronger immune response at higher doses. The use of cell culture systems to grow vaccines is a growing business and could potentially slice off months from the production process.
A new experimental flu vaccine produced using insect cells has shown promising results in early testing, demonstrating safety and immunogenic response in healthy adults. The vaccine, made using recombinant DNA techniques, offers a potential alternative to traditional egg-based vaccines.
Historical analyses of the 1918 Spanish influenza pandemic reveal that cities with early public health measures had lower peak weekly death rates and overall mortality compared to those that waited. Implementing multiple social containment measures within a few days of first local cases recorded cut peak death rates by up to half.
The University of Rochester Medical Center has been awarded a $26 million contract to establish the New York Influenza Center of Excellence, one of six nationwide centers focused on improving flu research. The center aims to develop more effective vaccines against seasonal influenza and future pandemics.
A new UCLA study found that practicing Tai Chi chih alone boosts immunity to a level comparable to the standard vaccine against shingles. Combining Tai Chi with the vaccine results in a clinically relevant boost and added benefits for middle-aged adults.
Developing an H5 vaccine faces hurdles in current egg production methods and the molecule's ability to stimulate an immune reaction, requiring two shots for full immunization. The ideal adjuvant must still be found to boost vaccine effectiveness.
Developing countries face a critical shortage of pandemic influenza vaccines, with only 500 million doses available globally. The WHO is urging international agreement to ensure affordable vaccine access for these nations, demonstrating global solidarity in the face of the next pandemic threat.
A recent global study found that a nasal spray flu vaccine reduced the attack rate of flu in children by 55 percent compared to traditional flu shots. The vaccine was well-tolerated and induced a more complete immune response, with fewer ear infections reported.
Researchers at St. Jude Children's Research Hospital found that the N1 protein in seasonal flu vaccines can trigger an antibody response to avian flu virus, offering cross-protection to some individuals. The study suggests that annual influenza vaccines may be beneficial to populations in areas where H5N1 poses a threat to humans.
A human trial of a DNA vaccine designed to prevent H5N1 avian influenza infection began in December 2006. The vaccine instructs human cells to make proteins that act as a vaccine against the virus, providing broad immune responses without infectious material.
A futures market for influenza activity has been created, predicting outbreaks two to four weeks in advance with high accuracy. The market aggregates expert opinions of healthcare providers, allowing for real-time analysis and informed decision-making in public health.
A University of Michigan study found that the traditional flu shot was effective in preventing influenza in healthy adults, while the live attenuated-virus nasal spray vaccine was less effective. The study compared the two vaccines head-to-head with laboratory confirmation and found significant differences in their protective effects.
The 2004 influenza vaccine shortage had a significant impact on continuity of care, with flu vaccination rates dropping by over 50% in some areas. Additionally, studies found that improper antibiotic use can exacerbate sinusitis symptoms and that patients with sore throats often seek pain relief rather than antibiotics.
A federal plan to vaccinate healthcare workers against smallpox had a low compliance rate and high variability among states. Researchers found that some states ranked poorly due to lack of support and ambivalent messages from authorities.
A powerful analysis reveals that only one-third of high-risk populations in Europe receive seasonal influenza vaccine, resulting in avoidable morbidity and mortality. Implementing EU vaccination recommendations could reduce the number of cases of death and illness from influenza, as well as contribute to flu pandemic preparedness.
A RAND Corporation study found that nursing homes with high staff and resident vaccination rates are less likely to experience flu outbreaks. Vaccination rates of over 55% for staff and 89% for residents were associated with a 60% reduction in influenza-like illness cases.
The U.S. Vaccine and Infectious Disease Organization has discovered a crucial pathway that supports the influenza A virus's ability to reproduce itself. This finding could lead to the development of new live vaccines and antiviral drugs for influenza epidemics and pandemics.
A Canadian study found that flu vaccines are associated with a small but increased risk of hospitalization for Guillain-Barré syndrome, a potentially debilitating neurological disorder. The absolute risk is very low, and the disorder affects about one in 100,000 individuals per year.
A large safety study found that the flu vaccine is not associated with an increased risk of serious conditions in young children. The study analyzed data on over 45,000 children who received the trivalent inactivated influenza vaccine between 1991 and 2003.
Scientists have developed a vaccine that protects mice against the 1918 influenza virus, which killed 50 million people worldwide. The vaccine works by stimulating antibodies capable of neutralizing the virus, providing a potential solution to future pandemic flu strains.
A booster shot given before a primary immunization may protect people against bird flu. Studies in Rochester suggest that adults who have never encountered the virus would benefit from an additional dose.
Researchers found that a prime-boost strategy using different subtypes of H5N1 vaccines significantly boosted immune responses in individuals with prior exposure. Additionally, an intradermal approach to delivering the vaccine showed promise but did not improve the immune response. These findings suggest pre-pandemic priming with exist...
The Journal of Infectious Diseases has published a supplement offering current information on pandemic and seasonal influenza, featuring leading experts discussing research and recommendations. The article highlights key findings on disease surveillance, vaccine manufacturing, and public health response plans.
A new study by mathematical biologists at The University of Texas at Austin recommends vaccine distribution strategies for potential shortages. The best approach depends on the contagiousness of the flu strain, with school children and high-risk groups being prioritized accordingly.
Researchers found that KEAP1 mutations in lung cancer cells increase NRF2 activity, leading to chemotherapy resistance. Meanwhile, a new study suggests targeting school-aged children for flu vaccination could help contain outbreaks.
Researchers have achieved effective immunity with a low dose of bird flu vaccine using MF59 adjuvant, potentially stretching vaccine supply. The study showed that antibody levels were significantly better and that a single dose of the adjuvanted vaccine was as good as two doses without adjuvant.
A clinical trial has demonstrated the efficacy of an H9N2 avian flu vaccine combined with an adjuvant in generating a strong antibody response in humans. The results suggest that even low doses of the vaccine can provide protection, making it a promising tool in pandemic prevention.
Researchers propose using existing facilities to produce vaccines from cell cultures, which could make enough doses to cover the US in just 3-4 months. This approach would reduce downtime and capital investments required for new dedicated facilities.
Researchers developed live attenuated vaccines using weakened influenza virus proteins and found they elicited broad and lasting immunity in mice and ferrets. The vaccines provided protection against different H5N1 viruses that emerged years later, demonstrating potential as a future treatment option for avian flu.
A new H5N1 influenza vaccine has produced a safe and effective immune response in healthy people at low doses, with the highest dose showing the best response. The vaccine was well-tolerated and did not have significantly more side effects compared to a placebo.
The University of Pittsburgh School of Medicine has received a $1.3 million grant to produce a promising avian flu vaccine that could protect against the deadly H5N1 virus. The vaccine, developed by Dr. Andrea Gambotto's team, has shown complete protection in mice and chickens against infection.
Researchers at MSU have developed a new cell line that can grow nearly all types of flu viruses, potentially leading to faster and cheaper vaccine production. This could help address the issues with traditional influenza vaccine production methods, including long production times and limited supply.
A new H5N1 vaccine has demonstrated cross-protection in ferrets against different variants of the virus, offering a promising solution for stockpiling in the event of a human outbreak. The vaccine was shown to completely protect ferrets from infection and reduce viral multiplication.
Researchers suggest that cholesterol-lowering drugs like statins could be useful in treating and preventing severe complications of the flu during a pandemic. Statins have anti-inflammatory and immunomodulatory effects that may also benefit people with influenza, making them a potential alternative to vaccines.
A new experimental vaccine has shown significant protective effects against multiple H5N1 strains in lab animals. The two-dose vaccination schedule induced higher levels of antibodies that were cross-reactive to various viruses, suggesting a potential solution for stockpiling vaccines during pandemics.
Researchers report improved survival rates with RP101, a novel compound being investigated as a potential therapeutic for advanced pancreatic cancer. In two studies, patients showed significant improvements in median survival and time to progression, offering hope for patients affected by the disease.
A new study explores how people make medical decisions, revealing that stepping into others' shoes can lead to better choices. By considering multiple perspectives, including those of doctors, parents, and medical directors, participants made treatment decisions that were more informed than their own self-interest would suggest.
A study found that higher dose flu vaccines significantly enhanced protection against naturally occurring influenza, increasing immunogenicity in the elderly. The research also showed that all three vaccine dosage levels were safe and well-tolerated.
A two-dose regimen of the H5N1 vaccine induced the highest antibody response after 42 days, with all formulations well-tolerated. However, the level of post-vaccination antibodies needed for protection against the H5 N1 virus remains unknown.
Five Spanish hospitals are participating in a phase III trial for an H5N1 influenza pandemic vaccine, alongside countries such as Germany, Holland, and France. The vaccine uses fractionated viral proteins and an adjuvant to stimulate the immune system, with the goal of improving vaccine production strategies.
A new study by St. Jude Children's Research Hospital has shown a DNA-based vaccine to be highly effective in protecting mice against lethal challenges with the H5N1 avian influenza virus. The vaccine targets two conserved viral proteins and one variable protein, providing complete protection in mice.
A recent study found that an intranasal influenza vaccine was significantly more effective in protecting young children against flu infection than traditional injections. The vaccine, known as CAIV-T, was 55% more effective in reducing influenza-like illness in children.
A new potential vaccine against deadly leishmaniasis has been developed by a research group led by Peter H. Seeberger, combining a virosome delivery system with a synthetic carbohydrate antigen. This innovative approach aims to overcome the limitations of existing vaccines and provide a strong protective action against the disease.
A large-scale model simulates the spread of a pandemic influenza virus in the US population, exploring the impact of interventions such as vaccination and social distancing. The study finds that stockpiling vaccines and implementing a combination of mitigation strategies could be effective in slowing the spread of the flu.
The American College of Physicians emphasizes the need for a comprehensive healthcare response to pandemic influenza, highlighting the critical role of primary care physicians. The organization recommends hands-on clinical training for internists to address public health crises like pandemic influenza.
The Duke study aims to determine whether a modified form of the investigational bird flu vaccine can trigger a strong immune response at lower doses. The seven-month trial will test varying strengths of the H5N1 vaccine, either with or without an aluminum hydroxide adjuvant.
The H5N1 avian flu vaccine has shown promise in inducing immune responses in healthy adults. Among the 99 participants who received the high-dose vaccine, 54% developed neutralizing antibodies to the vaccine at a serum dilution of 1:40 or greater.
Researchers found that a dose of 90 micrograms per shot was most effective in producing protective antibodies against bird flu. To make the vaccine available to more people, studies are underway to test an adjuvant called alum, which could allow for reduced doses and increased supply.
Researchers aim to offer protection to immunocompromised patients without unnecessary vaccination. They will measure T cell and B cell counts to determine which patients benefit from an influenza vaccine, with potential customized treatment recommendations for each group.
A novel vaccine has been shown to be effective in preventing middle ear infections in young children, reducing episodes by about a third. The vaccine targets the bacteria Streptococcus pneumoniae and Haemophilus influenzae, which are leading causes of infection.
A new influenza vaccine using a purified protein from the virus's surface has been developed, showing safety and immunity equal to traditional egg-based vaccines. The vaccine is expected to be produced within 4 weeks and at a cost comparable to traditional methods, providing a significant advantage in fighting potential pandemics.
A Vanderbilt University Medical Center study found that media coverage had a significant impact on pediatric flu vaccination rates nationwide. The study surveyed 256 parents and found that 75% of children with confirmed influenza dates received the vaccine after mid-November 2003, influenced by media attention.
A nationwide study of vaccinating school children against influenza could reduce community transmission and improve vaccine production. The authors suggest a collaboration between academia, government, and industry to conduct such a study.
Researchers genetically engineered an adenovirus to produce a protein from the H5N1 influenza virus, protecting mice from death and weight loss when infected with the virus. The human adenovirus vaccine generated specific T cells that helped clear the virus, offering a viable option for potential pandemic vaccination.
A vaccine developed by University of Pittsburgh Medical Center researchers has shown 100% protection against the avian flu virus in an animal study. The vaccine, which contains a live virus, stimulates several lines of immunity and is expected to have greater therapeutic value than traditional vaccines.
Leading NIAID researchers explore the complex relationship between influenza viruses and the human immune system. They explain how antigenic drift and shift impact vaccine development, highlighting potential vulnerabilities to flu pandemics.
The National Institutes of Health is testing avian influenza vaccines to prevent a possible pandemic. Saint Louis University School of Medicine is conducting a research study using a killed flu virus vaccine in children ages 2-9.